Pentoxifylline versus Steroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss with Diabetes

Lan, Wei-Che; Wang, Ching-Yuan; Lin, Chia‐Der

doi:10.5152/iao.2018.4690

Cited by 8 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sudden deafness is a sudden onset of sensorineural hearing loss manifested as unilateral hearing loss, which can be accompanied by tinnitus, ear blockage, dizziness, nausea, and vomiting. It usually occurs suddenly within 72 hours, and the hearing loss of two adjacent frequencies can be found to be greater than or equal to 20 dBHL during pure tone audiometry [ 22 ]. The causes of sudden deafness are more complicated and may be related to factors such as inner ear blood supply disorder and viral infection [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Ginkgo biloba Extract Combined with Hormones in the Treatment of Sudden Deafness and Its Effect on the Reactivity of Peripheral Blood T Cell Subsets

Zhu

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

This work was aimed at exploring the efficacy of Ginkgo biloba extract combined with hormones in the treatment of sudden deafness and the influence on the reactivity of peripheral blood T cell subsets (PBTCSs). In this work, 64 patients with sudden deafness who were treated in The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine from August 2019 to August 2022 were selected as the research objects. The patients were randomly divided into a hormone group (treatment with prednisone acetate, n = 34 ) and a combination group (treatment with Ginkgo-Damole combined with prednisone acetate, n = 30 ). After the two groups of patients were treated in different ways, their efficacy, symptom improvement, changes in blood rheology, and PBTCSs were compared. The total effective rates (TERs) of the hormone group and the combination group were 76.32% and 95.73%, respectively ( P < 0.05 ). The fibrinogen contents of the patients in the combination group were obviously lower than those in the hormone group after 5 d, 7 d, and 10 d of treatment ( P < 0.05 ). The high blood viscosity (HBV) values of patients in the combination group at 5 d, 7 d, and 10 d after treatment were greatly lower than those in the hormone group ( P < 0.05 ). The low blood viscosity (LBV) values after 3 d, 7 d, and 10 d of treatment in the combined group were much lower in contrast to those in the hormone group ( P < 0.05 ). The CD3+, CD4+, and CD4+/CD8+ in peripheral blood in the combination group were sharply higher while the CD8+ in the combined group was lower in contrast to the hormone group ( P < 0.05 ). There was no visible difference in the incidence of adverse reactions between the two groups of patients after treatment ( P > 0.05 ). In conclusion, the combined application of Ginkgo biloba extract and hormones could effectively improve the abnormal hemorheological indexes of patients with sudden deafness and effectively relieve the imbalance of PBTCSs, which was safe.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Ginkgo biloba Extract Combined with Hormones in the Treatment of Sudden Deafness and Its Effect on the Reactivity of Peripheral Blood T Cell Subsets

Zhu

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Oral or IV applied systemic steroids are standard recommended eff ective treatment modality, and also the most frequently used management of SSNHL. 10,11 Lan et al…”

Section: Discussionmentioning

confidence: 99%

“…found that systemic corticosteroid therapy were not superior to Pentoxifylline treatment for the management of SSNHL in patients with Diabetes Mellitus. 10 We preferred to apply IV systemic corticotherapy (prednisolone) to all our patients because all of the patients were hospitalized and had vascular access. Corticosteroids also can be given to SSNHL patients as local application via intratympanic injection primarily or as a salvage management successfully.…”

Section: Discussionmentioning

confidence: 99%

Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği

Özdamar¹,

Acar²

2021

Sakarya Medical Journal

View full text Add to dashboard Cite

Objective Management of sudden sensorineural hearing loss still remains unclear in otology. To evaluate our experience medical management of sudden hearing loss with review of the literature. Materials and MethodsIn this study, we performed retrospective chart review including 60 patients presenting sudden sensorineural hearing loss (SSNHL) between 2008-2018 years. We included only patients given medical management, and hyperbaric oxygen was not performed in any patients. Pure tone audiometric measurements investigated before (PTA I) and after treatment at two weeks (PTA II) and three months (PTA III). We also performed cranial MRI on all patients to disclose intracranial pathology if it was present.Results The mean age of our cases of was 49.7 years. No certain etiology was detected in all patients in the study. The improvement of hearing loss in our cases was classified according to Siegel's criteria as follows: Type I (3.3%) in 2 patients, Type II (16.7%) in 10 patients, Type III (33.3%) in 20 patients, Type IV (28) in 28 patients (46.7%). Three mean audiometric measurements were compared statistically with each other (PTA I and PTA II: p <0.05; PTA I and III: p <0.05, PTA II and III: p <0.05). ConclusionIn current study, we found that 60 patients diagnosed as SSNHL and given only medical treatment had positive satisfactory hearing improvement who was observed mainly in that patients with moderate to severe hearing loss and younger ones; however, these results require prospective studies involving a large number of patients.Keywords Sudden hearing loss; sensorineural hearing loss; drug therapy management. ÖzAmaç Ani sensörinöral işitme kaybının tedavisi otolojide hala belirsizliğini korumaktadır. Bu çalışmanın amacı ani işitme kaybının tıbbi yönetimi konusundaki deneyimlerimizi literatür eşliğinde değerlendirmektir. Gereç ve YöntemlerBu çalışmada 2008-2018 yılları arasında ani sensörinöral işitme kaybı olan 60 hastadan oluşan retrospektif inceleme tablosu yaptık. Sadece tıbbi tedavi verilen hastaları dahil ettik ve hiçbir hastaya hiperbarik oksijen uygulanılmadı. Saf ses odyometrik ölçümler tedaviden önce (PTA I), ve tedaviden sonra ikinci hafta (PTA II) ve üçüncü ayda (PTA III) yapıldı. Eğer varsa intrakranial bir patolojiyi ortaya çıkarmak için tüm hastalara kranial MRI uygulandı.

show abstract

“…Pentoxifylline is a hemorheologically active phosphodiesterase inhibitor that is a treatment option for sudden sensorineural hearing loss [8][9][10]. Recent data also suggest that pentoxifylline protects the inner ear from amikacin-induced ototoxicity [11].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous treatment with pentoxifylline does not adversely affect the neurotrophic effects of brain-derived neurotrophic factor on spiral ganglion neurons

Geißler¹,

Blumenstock²,

Gabrielpillai³

et al. 2021

NeuroReport

View full text Add to dashboard Cite

The hemorheologic drug pentoxifylline is applied for the treatment of sudden sensorineural hearing loss and tinnitus to improve cochlear microcirculation. Recent studies also suggest protective and trophic effects on neuronal cells. Because the preservation of sensorineural structures of the inner ear is fundamental for normal hearing and hearing restoration with auditory prostheses, pentoxifylline and neurotrophic factors such as brain-derived neurotrophic factor (BDNF) are promising candidates to treat degenerative disorders of the inner ear. We used an in-vitro model to determine the neurotrophic effects of these factors on spiral ganglion cells from postnatal rats. Pentoxifylline, alone and in combination with BDNF, was added at various concentrations to the cultured cells. Cells were immunolabeled and analyzed to determine neuronal survival, neurite length, neuronal branching and morphology. Pentoxifylline did not significantly increase or decrease neuronal survival, neurite length and neuronal branching compared to control cultures. Analysis of cellular morphology showed that diverse neuronal subtypes developed in the presence of pentoxifylline. Our data revealed that pentoxifylline did not interfere with the robust neurotrophic effects of BDNF on spiral ganglion neurons when cultured cells were treated with pentoxifylline and BDNF simultaneously. The results of our study do not suggest major neurotrophic effects of pentoxifylline on cultured spiral ganglion neurons. Because pentoxifylline has no detrimental effects on spiral ganglion neurons and does not reduce the effects of BDNF, both agents could be combined to treat diseases of the inner ear provided that future in vivo experiments and clinical studies support these findings.

show abstract

Pentoxifylline versus Steroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss with Diabetes

Cited by 8 publications

References 18 publications

Efficacy of Ginkgo biloba Extract Combined with Hormones in the Treatment of Sudden Deafness and Its Effect on the Reactivity of Peripheral Blood T Cell Subsets

Efficacy of Ginkgo biloba Extract Combined with Hormones in the Treatment of Sudden Deafness and Its Effect on the Reactivity of Peripheral Blood T Cell Subsets

Ani Sensörinöral İşitme Kaybı Olan Hastalarda Tıbbi Tedavinin Etkinliği

Simultaneous treatment with pentoxifylline does not adversely affect the neurotrophic effects of brain-derived neurotrophic factor on spiral ganglion neurons

Contact Info

Product

Resources

About